Danish leader will face a challenging landscape among competitors ...

Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.

Novo Nordisk's new CEO, Maziar Mike Doustdar, is tasked with revitalizing the company's flagging sales and addressing ...

COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

The new CVS contract for Wegovy and stepped-up direct-to-patient outreach offer concrete levers to boost U.S. volume as early as Q3, helping to stabilize demand in the face of compounding pharmacy ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

NVO has been struggling on the charts since its late-April bottom at $57, with recent pressure at the $70 region. So far in ...

It’s not unusual for a non-national to be CEO, executive director, or president of a company in a country. “C-level” positions and top management roles are often international. However, when the ...

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...